2-[3-(2-methyl-1H-imidazol-1-yl)propyl]-1H-isoindole-1,3(2H)-dione | 101225-81-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-[3-(2-methyl-1H-imidazol-1-yl)propyl]-1H-isoindole-1,3(2H)-dione
• 英文别名: N-[3-(2-Methylimidazol-1-yl)propyl]phthalimide；2-[3-(2-methylimidazol-1-yl)propyl]isoindole-1,3-dione
• CAS: 101225-81-4
• 化学式: C₁₅H₁₅N₃O₂
• 分子量: 269.303
• InChiKey: QEZYEJSCCCDVND-UHFFFAOYSA-N

物化性质

• 熔点：
  122-125 °C
• 沸点：
  474.8±28.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  55.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[3-(2-methyl-1H-imidazol-1-yl)propyl]-1H-isoindole-1,3(2H)-dione 在 肼 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 2-甲基-1H-咪唑-1-丙胺
  参考文献：
  名称：

  WO2007/77510

  摘要：

  公开号：
• 作为产物：
  描述：

  2-甲基咪唑 、 N-(3-溴丙基)苯二胺 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 2-[3-(2-methyl-1H-imidazol-1-yl)propyl]-1H-isoindole-1,3(2H)-dione
  参考文献：
  名称：

  WO2007/77510

  摘要：

  公开号：

文献信息

• Compounds and Methods for the Treatment of Viruses and Cancer
  申请人：Jorgensen William L.

  公开号：US20100222352A1

  公开（公告）日：2010-09-02

  The present invention relates to compounds according to the formula I: Where R a is H or an optionally OH-substituted C 1 -C 3 alkyl; R 1 is OR 1 , an optionally substituted C 4-12 carbocyclic group which may be saturated or unsaturated (including aromatic) or an optionally substituted heterocyclic group; R 1 is an optionally substituted C 1 -C 14 hydrocarbyl group or an optionally substituted heterocyclic group; R 2 , R 3 and R 4 are each independently H, an optionally substituted C 1 -C 4 alkyl group (preferably CH 3 , CH 2 CH 3 or CF 3 ), halogen (preferably F, Cl, Br), OR, CN, NO 2 , a C 1 -C 6 thioether, a C 1 -C 6 thioester group, an optionally substituted CO 2 R group, an optionally substituted COR group or an optionally substituted OCOR group (preferably R 4 is H); R is H or an optionally substituted C 1 -C 6 alkyl group; RHET is an optionally substituted heterocyclic group; and pharmaceutically acceptable salts, solvates or polymorphs thereof.

  本发明涉及公式I的化合物：其中R为H或可选择的OH取代的C1-C3烷基; R1为OR1，可选择取代的C4-12碳环基，可饱和或不饱和（包括芳香族）或可选择取代的杂环基; R1为可选择取代的C1-C14烃基或可选择取代的杂环基; R2、R3和R4各自独立地为H、可选择取代的C1-C4烷基（优选为CH3、CH2 或CF3）、卤素（优选为F、Cl、Br）、OR、CN、NO2、C1-C6硫醚、C1-C6硫酯基、可选择取代的CO2R基团、可选择取代的COR基团或可选择取代的OCOR基团（优选R4为H）; R为H或可选择取代的C1-C6烷基; RHET为可选择取代的杂环基;以及其药学上可接受的盐、溶剂或多晶体。
• MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：Kumar Naresh

  公开号：US20100222393A1

  公开（公告）日：2010-09-02

  Compounds of Formula (I), wherein represents a single bond when G is —OH and double bond when G is —O; R 1 and R 2 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl; R 3 is selected from the group selected from hydrogen, hydroxy, alkoxy, alkenyloxy or alkynyloxy; X is selected from oxygen, —NH, —NR (wherein R is alkyl, alkenyl, alkenyl, alkynyl or aryl), sulphur or no atom; Het is heterocyclyl or heteroaryl; n is an integer from 1 to 6; are muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and 4 i gastrointestinal systems mediated through muscarinic receptors.

  式(I)的化合物，其中当G为—OH时表示单键，当G为—O时表示双键；R1和R2分别选自氢、烷基、烯基、炔基、芳基烷基、环烷基、芳基、杂芳基、杂环烷基、杂环烷基烷基或杂芳基烷基；R3选自氢、羟基、烷氧基、烯氧基或炔氧基所选的群；X选自氧、—NH、—NR（其中R为烷基、烯基、炔基、芳基或烷基芳基）、硫或无原子；Het为杂环烷基或杂芳基；n为1至6的整数。这些化合物是肌肉性乙酰胆碱受体拮抗剂，可用于治疗通过肌肉性乙酰胆碱受体介导的呼吸系统、泌尿系统和胃肠系统的各种疾病，除其他用途外。
• Phthalimide‐tethered imidazolium salts: Synthesis, characterization, enzyme inhibitory properties, and in silico studies
  作者：Murat Yiğit、Yeliz Demir、Duygu Barut Celepci、Tuğba Taskin‐Tok、Ali Arınç、Beyhan Yiğit、Muhittin Aygün、İsmail Özdemir、İlhami Gülçin

  DOI：10.1002/ardp.202200348

  日期：2022.12

  imidazolium salts were prepared in good yield by the reaction between 1-alkylimidazole and a variety of alkyl halides. The structures of the compounds were identified by FT-IR, 1H NMR, and 13C NMR spectroscopy, elemental analysis, and mass spectrometry. The crystal structure of 1b was determined by the single-crystal X-ray diffraction method. The phthalimide-tethered imidazolium salts exhibited inhibition

  通过1-烷基咪唑与多种烷基卤化物的反应，以良好的收率制备了一系列新的咪唑鎓盐。通过红外光谱、1 H NMR、13 C NMR光谱、元素分析和质谱鉴定了化合物的结构。1b的晶体结构通过单晶X射线衍射法确定。邻苯二甲酰亚胺系咪唑盐对乙酰胆碱酯酶 (AChE) 和人碳酸酐酶 (hCAs) I 和 II 具有抑制能力，其中K iAChE 的值范围为 24.63 ± 3.45 至 305.51 ± 35.98 nM，hCA I 的值为 33.56 ± 3.71 至 218.01 ± 25.21 nM，hCA II 的值为 17.75 ± 0.96 至 308.67 ± 13.73 nM。结果表明，新型咪唑盐在阿尔茨海默病、癫痫、青光眼和白血病的治疗中发挥关键作用，这与其对hCA I、hCA II和AChE的抑制能力有关。分子对接和计算机吸收、分布、代谢、排泄和毒性研究用于研究咪唑盐如何与特定蛋白质靶
• Thromboxane synthetase inhibitors and antihypertensive agents. 2. N-[(1H-Imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones and N-[(1H-1,2,4-triazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones as unique antihypertensive agents
  作者：Jeffery B. Press、William B. Wright、Peter S. Chan、Joseph W. Marsico、Margie F. Haug、Jess Tauber、Andrew S. Tomcufcik

  DOI：10.1021/jm00155a036

  日期：1986.5

  A series of N-[(1H-heteroaryl)alkyl]-1H-isoindole-1,3(2H)-diones were prepared as part of a continuing investigation into the biological properties of compounds that were both thromboxane synthetase inhibitors and potential antihypertensive agents. The most active thromboxane synthetase inhibition was found for the title imidazole derivatives wherein a hexyl or octyl chain separated the heterocyclic ends of the molecule (5,6) or with substitution on the isoindole portion of the molecule (18, 19, 21, 22, 25, 26). Compounds with shorter alkyl chain separations had good antihypertensive effects (1-5, 8-10, 19-22, 27-30). Butyl derivative 3 was chosen for further evaluation as a potential antihypertensive agent with thromboxane synthetase inhibitory properties.
• PRESS J. B.; WRIGHT W. B., JR.; CHAN P. S.; MARSICO J. W.; HAUG M. F.; TA+, J. MED. CHEM., 29,(1986) N 5, 816-819
  作者：PRESS J. B.、 WRIGHT W. B., JR.、 CHAN P. S.、 MARSICO J. W.、 HAUG M. F.、 TA+

  DOI：——

  日期：——